Registration is Open: www.team-share.net/Natural_History_Studies_Rare_Diseases.

Slides:

Advertisements

Similar presentations

Academic Industry Interactions - workshop. Motivations and Challenges Many research intensive universities have research budgets where

Advertisements

1 FDA Industry Workshop Statistics in the FDA & Industry The Future David L DeMets, PhD Department of Biostatistics & Medical Informatics University of.

EU rare diseases registry for Niemann-Pick Disease type A, B and C Tarekegn Hiwot Consultant in Inherited Metabolic Disorders University Hospital of Birmingham.

Topic 1 What is patient safety?. Learning objective Understand the discipline of patient safety and its role in minimizing the incidence and impact of.

Session A Crisis and Emergency Risk Communication* *Adapted from CDC Crisis and Emergency Risk Communication (CERC) Training.

Biopharmaceutical Section of the American Statistical Association 1 Biopharmaceutical Section.

Engaging Students Through Lectures Making overt the thought processes used by pharmacists in the dynamic area of medication management Dr Michael Ward.

Why Write A Grant? Howard Bauchner, MD Professor of Pediatrics and Public Health Vice-Chair, Academic Affairs Department of Pediatrics Boston Medical Center.

Clinical Trials with SARC We’re here to help.. What can SARC do for you? Provide help developing a research idea Provide help with contacting pharma Provide.

Pharmacogenomics: Implications for CNS Drug Development in the 21st Century Challenges for Development & Approval – Patient & Funding Agency Perspective.

BIOMARKERS/BIOSIGNATURES Standards needed for Translational Research 1.Standardized QUESTIONS in Clinical Trials 2.Standardized PRACTICES in advancing.

By Kevin Anderson. What is UpToDate?  UpToDate.com is a database composed of thousands of evidence-based clinical studies and peer-reviewed by more than.

Physician Symposium on Quality Improvement November 12, 2009 Bob McArtor, MD Clinical Advisor MaineHealth.

Upper GI Research and Clinical Trials Update Bridget Workman Research Manager NECRN N 21 ST November 2012.

CPTR Overview CPTR 2012 Workshop October 2-4, 2012.

Activities at Academic Research Centers: Identifying Present Activities and Future Opportunities ICORD V February 24, 2009 Jim Cloyd, PharmD Lawrence Weaver.

Adding ORDR Rare Diseases Terms to MeSH Tree Structure Stephen C. Groft, Pharm. D. Director, office of Rare Diseases Research National Institutes of Health.

Transition of Biomarkers to Surrogate Endpoints: A Critical Path Initiative….. …..Introduction Clinical Pharmacology Subcommittee of ACPS November 4, 2004.

Cost-effectiveness of Screening Tests Mark Hlatky, MD Stanford University.

Sanitary Regulation in tourism. Pre-Travel Health Consultation.

Embedding CRED Training Day. Timing: ~ Introductory session (2 hours) ~ One training day (6 hours) ~ Follow-up sessions (2 hours) Focus: ~ Embedding of.

PaRROT Program Introduction. Learning objectives Understand and be aware of: History, objectives principles and expected outcomes of PaRROT Program content,

Women and Trials in High-Income Settings: Clinical Investigator Perspective Judith S. Currier, MD University of California, Los Angeles.

TUNING PROJECT (MEDICINE) INTERIM ANALYSIS OF SURVEY QUESTIONNAIRE May 2006

Clinical Research and Outcomes Registry Workshop Creating an Informed Consent Form Daniel Ford, MD, MPH Joseph Carrese, MD.

ICARE Member Reports National Institutes of Health/National Institute of Neurological Disorders and Stroke NIH Mission: NIH is the steward of medical and.

FIDIC Events FIDIC offers a broad range of training-related activities.

The Portuguese Programme on Rare Diseases José Marques Robalo Deputy Director-General of Health Ministry of Health Portugal.

NIAMS Extramural Scientific Planning Retreat 2013 April 4, 2013 Session 1: Strategies for Successful Rare Disease Clinical Trials.

Promising Technologies for Contemporary Development 2pm-5pm April 15, 2016.

Research Speed Updating: Health and wellbeing 9 July 2014.

The Clinical studies group Who are we What do we do How do we do it How can you get involved.

Version: 27 May 2007 New Models for Collaboration: Patients as Drivers and Partners in Neurological Research Integrating Patient Input Within the Drug.

Preparing for Lectures and Seminars What’s so different? Study Skills Workshops 2015.

HCS 457 Week 1 DQ 3 What are the 3 key legal principles that underlie both public health and healthcare law in the US? What were your thoughts when reading.

__ Contact Hours will be awarded for this activity.

2010 Organic Pest Management Training Events

Institute for Educators In Nursing and Health Professions

Surya Chitra, PhD MBA Director Biostatistics Endo Health Solutions

Support- IRDiRC Proposed Work Plan And Communication Strategy

Myotonic Dystrophy Foundation

Childhood cancer registration in England: 2015 to 2016, National Cancer Registration and Analysis Service Charts from the report.

Online PD What Does The Data say?

Multiple Organ Dysfunction Syndrome (MODS)

“Clinical Research Perspective”

IBD Therapies: Guidance for Managed Care Professionals

Patient-Centered Clinical Method

Forum for Collaborative Research:

Cardiogenic Shock.

Faculty/Presenter Disclosure

“2nd World Congress on Rare Diseases and Orphan Drugs”

KEY STAKEHOLDERS PERCEPTIONS OF HEOR USAGE IN LEBANON

مطالعات اپیدمیولوژیک.

IASC Health Cluster Advocacy Plan

دانشگاه علوم پزشکی بوشهر دانشکده بهداشت

دانشگاه علوم پزشکی بوشهر دانشکده بهداشت

Multiple Sclerosis Rare disease < 200,000 cases per year

UK IT Industry Awards – UK Public Sector Project of the Year

18 Weeks Measurement Workshop 23 November 2010

Pediatric Clinical investigator training workshop

Hypovolemic Shock.

Session: 9 On-going Monitoring & Follow Up

STRATEGIC ACTION IN HEALTH (AES)

Nonprofit Funder – Research Institution Partnership Workshop

12th – 13th November GRANADA

Faculty/Presenter Disclosure

Session 3 The New MDG Framework

TITLE OF PRESENTATION Name of Presenter.

Next Generation Sequencing Market. Report Description and Highlights According to Renub Research market research report “Next Generation Sequencing (NGS)

Presentation transcript:

Registration is Open: www.team-share.net/Natural_History_Studies_Rare_Diseases

Workshop on Natural History Studies of Rare Diseases: Meeting the Needs of Drug Development and Research Importance of Natural History Studies Provide understanding of the etiology and progression of rare diseases Yield information on biomarkers and other correlates of clinical outcome Workshop Highlights Discussions on principles and applications of studies of the natural histories of rare diseases Session topics related to study designs and case studies Audience Academic and clinical researchers, industry R & D, public health agencies, disease advocacy groups